Metformin Dosis Rendah Jangka Pendek dan Risiko Timbulnya Aterosklerosis pada Prediabetes Non Obes

Abstract

Background: The establishment of macrovascular (cardiovascular) event is initiated in the period of prediabetic. Metformin plays role in the carbohydrate and lipid metabolism as well as vascular protection. The mechanism of the cardiovascular event risk increase in the prediabetic individual has not been clearly established. The study was to determine if insulin resistance control by low-dose short-term metformin administration in the non-obese prediabetic individual might decrease the atherosclerosis risk. Method: The present study was a prospective, experimental study with pretest-posttest control group design. It was conducted on the first degree relative of type-2 DM patient who met the criteria of non-obese prediabetic individual. Subjects were randomly classified into treatment group (designed for metformin administration), and the control group (designed for placebo administration). The prediction of atherosclerosis risk was based on the hsCRP, PAI-1, VCAM-1 and fibrinogen levels. Results: The margin between pre and post metformin administration term were 1.89 vs 0.06 mg/L (p=0.001), 1.42 vs 0.84 IU/mL (p=0.015), 180.85 vs 03.81 mg/L (p=0.061) and 80.15 vs 31.42 mg/dL (p=0.001) for hsCRP, PAI-1, VCAM-1 and Fibrinogen in the treatment and control group, respectively. Conclusion: Low-dose short-term metformin administration might decrease the atherosclerosis risk factor in the non-obese prediabetic individuals.